# Press Releases

### July 22, 2026

- **[Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management](/content/news/3hbxchsjl1-targeting-the-100-billion-market-insilic/index.html)**  
- **July 14, 2026**

- **[Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development](/content/news/xa31uheux1-insilico-medicine-and-bora-pharmaceutica/index.html)**  
- **July 12, 2026**

- **[Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases](/content/news/2fx6em2jc1-deepening-collaboration-in-ai-powered-ra/index.html)**  
- **July 08, 2026**

- **[Insilico Medicine Releases Positive Profit Alert for the First Half of 2026](/content/news/6f8yhr6sl1-insilico-medicine-releases-positive-prof/index.html)**  
- **July 07, 2026**

- **[Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis](/content/news/xmjsn4l091-insilico-initiates-phase-iii-clinical-tr/index.html)**  
- **July 06, 2026**

- **[Pharma.AI Q2 2026 Summer Webinar: A Deep Dive into Insilico Medicine’s Latest Platform Upgrades](/content/news/er6gnm3741-pharmaai-q2-2026-summer-webinar-a-deep-d/index.html)**

### 2023

- **[Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target](https://www.globenewswire.com/news-release/2023/01/10/2586249/31533/en/Insilico-Medicine-announces-positive-topline-results-of-the-New-Zealand-Phase-1-trial-of-INS018_055-an-AI-designed-drug-for-an-AI-discovered-target.html#:~:text=New%20York%2C%20Jan.%2010%2C%202023%20%28GLOBE%20NEWSWIRE%29%20--,end-to-end%20AI%20platform%20for%20idiopathic%20pulmonary%20fibrosis%20%28IPF%29)** **10-JANUARY-2023**

- **[Insilico announces the expansion of its oncology pipelines and delivers the new generation FGFR2/3 inhibitor](https://www.eurekalert.org/news-releases/1029927)** **28 December 2023**

- **[Insilico announces the second generation DGKA inhibitor for the treatment of PD-1/PD-L1 resistance solid tumors](https://www.eurekalert.org/news-releases/1029877)** **26 December 2023**

- **[Insilico Medicine leadership to attend 42nd Annual J.P. Morgan Healthcare Conference](https://www.eurekalert.org/news-releases/1029306)** **18 December 2023**

- **[Insilico Medicine announces AI drug discovery milestone achievement in pharma collaboration](https://www.eurekalert.org/news-releases/1010901)** **12 December 2023**

### 2022

- **[Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation](https://www.prnewswire.com/news-releases/insilico-medicine-announces-the-nomination-of-two-preclinical-candidates-for-phd2-12-months-after-program-initiation-301454231.html#)** **05-JAN-2022**

- **[Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology](https://www.eurekalert.org/news-releases/974934)** **20-DECEMBER-2022**

- **[Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI](https://www.eurekalert.org/news-releases/972062)** **16-NOVEMBER-2022**

- **[Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit](https://www.eurekalert.org/news-releases/971576)** **16-NOVEMBER-2022**

- **[Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion](https://www.globenewswire.com/news-release/2022/11/08/2551039/31533/en/Insilico-Medicine-Signs-Strategic-Research-Collaboration-with-Sanofi-worth-up-to-1-2-Billion.html)** **8-NOVEMBER-2022**

- **[Deepfake Technology in Drug Design. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event](https://www.globenewswire.com/news-release/2022/10/20/2538669/0/en/Deepfake-Technology-in-Drug-Design.html)** **20-OCTOBER-2022**

- **[Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities](https://www.globenewswire.com/news-release/2022/09/14/2516095/0/en/Saudi-Ministry-of-Investment-and-Insilico-Medicine-sign-agreement-to-expand-region-s-biotechnology-capabilities.html)** **10-SEPTEMBER-2022**

- **[Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million](https://www.globenewswire.com/news-release/2022/08/10/2495798/0/en/Insilico-Medicine-Announces-New-Investment-Led-by-Aramco-backed-Prosperity7-Ventures-bringing-total-Series-D-Financing-to-95-Million.html)** **10-AUGUST-2022**

- **[Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine](https://www.globenewswire.com/news-release/2022/07/07/2475900/31533/en/Insilico-Medicine-identified-multiple-new-targets-for-amyotrophic-lateral-sclerosis-ALS-using-its-AI-driven-target-discovery-engine.html)** **07-JULY-2022**

- **[Insilico Medicine appoints Dr. Feng Ren as co-CEO](https://www.prnewswire.com/news-releases/insilico-medicine-appoints-dr-feng-ren-as-co-ceo-301569586.html?tc=eml_cleartime)** **16-JUNE-2022**

- **[Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Automated Laboratory](https://www.prnewswire.com/news-releases/insilico-medicine-raises-60-million-in-series-d-financing-to-advance-pipeline-and-launch-ai-powered-drug-discovery-robotics-laboratory-301561736.html?tc=eml_cleartime)** **06-JUNE-2022**

- **[Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment](https://www.prnewswire.com/news-releases/insilico-medicine-announces-novel-3cl-protease-inhibitor-preclinical-candidate-for-covid-19-treatment-301553766.html?tc=eml_cleartime)** **24-MAY-2022**

- **[CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World](https://www.cbinsights.com/research/report/artificial-intelligence-top-startups-2022/)** **17-MAY-2022**

- **[Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers](https://www.prnewswire.com/news-releases/insilico-medicine-expands-synthetic-lethality-portfolio-with-nomination-of-a-preclinical-candidate-targeting-mat2a-for-the-treatment-of-mtap-deleted-cancers-301540618.html?tc=eml_cleartime)** **05-MAY-2022**

- **[Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders](https://www.prnasia.com/story/357993-1.shtml)** **13-APR-2022**

- **[Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform](https://www.prnewswire.com/news-releases/insilico-medicine-applauded-by-frost--sullivan-for-enabling-rapid-and-cost-effective-drug-discovery-and-development-with-its-pharmaai-platform-301467147.html?tc=eml_cleartime)** **25-JAN-2022**

- **[Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets](https://www.prnewswire.com/news-releases/fosun-pharma-and-insilico-medicine-announce-a-strategic-ai-driven-drug-discovery-and-development-collaboration-to-jointly-advance-multiple-targets-301457569.html?tc=eml_cleartime)** **11-JAN-2022**

- **[Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference](https://www.prnewswire.com/news-releases/insilico-medicine-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-301455645.html)** **06-JAN-2022**